Skip to content

Less Invasive Beractant Administration in Preterm Infants

Less Invasive Beractant Administration in Preterm Infants: a Pilot Study.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02611284
Enrollment
60
Registered
2015-11-20
Start date
2013-10-31
Completion date
2015-03-31
Last updated
2021-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infant, Premature

Keywords

Beractant, Feasibility Studies, Infant, Premature, Noninvasive Ventilation

Brief summary

The aim of this study is to assess the efficacy and feasibility of a new less invasive surfactant administration (LISA) technique with a specific designed cannula for surfactant administration using Beractant replacement in preterm infants \<32 weeks of gestation and compare short and long term outcomes with the intubation, administration of surfactant and extubation method (INSURE). This was a single-center, prospective, open-label, non-randomized, controlled study with an experimental cohort of 30 patients treated with LISA and a retrospective control group comprising the 30 most recently treated patients with INSURE. Beractant (4 ml/Kg) was administered as exogenous surfactant in both groups if patients on nasal continuous positive airway pressure (nCPAP) during the first three days of life were needed of more than 30% of fraction of inspired oxygen inspired oxygen fraction (FiO2).

Interventions

PROCEDURELISA

All infants were supported with nCPAP while breathing spontaneously during instillation. A 5Frenchgamma sterilized multi-access catheter specifically designed to deliver surfactants for Neonates was placed 1-2 cm below the vocal cords by direct laryngoscopy without the use of a Magill forceps. Beractant was used as exogenous natural surfactant, (100mg/kg; 4ml/kg) and administered in two aliquots during 1-3 minutes. Positive pressure inflations were given by a mask and bag only if the infant was apneic or bradycardia develops despite the interruption of the procedure. The surfactant administration catheter was removed after surfactant instillation and nCPAP support was maintained. A second dose of surfactant was administered during the first 3 days of life if more than 40% of FiO2 was needed while on nCPAP with at least 6 cm H2O pressure.

PROCEDUREINSURE

The INSURE technique was performed using Beractant (4ml/kg) after endotracheal intubation. A multi-access catheter for Neonates/Pediatrics designed to deliver surfactants (KimVentTrach Care Technology ®, United Kingdom) was pre-connected to the endotracheal tube and used for surfactant administration without having to disconnect the ventilator. While surfactant was administered all infants were connected to pressure support ventilation modality (PSV) combined with volume guarantee (VG), Dräger ventilator). A tidal volume of 4ml/kg was initially adjusted. After surfactant administration, all infants were to be extubated, in accordance with our institutional extubation guidelines, if FiO2\< 0.35; for a target Oxygen Saturation (SpO2) of \>90%, and if a consistent respiratory effort was present. Extubation was supported with nCPAP in all patients.

Sponsors

Hospital General Universitario Gregorio Marañon
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Minutes to 3 Days
Healthy volunteers
No

Inclusion criteria

* Preterm infants of less than 32 weeks of gestation (WG)breathing spontaneously on nCPAP during the first three days of life that met exogenous surfactant administration criteria (Table l) were eligible to enroll in the study

Exclusion criteria

* Infants who met intubation criteria (Table 1) at the moment of the surfactant administration were excluded in both groups.

Design outcomes

Primary

MeasureTime frameDescription
% patients >1 h of mechanical ventilationthrough study completion, an average of 1 yearThe percentage of patients that required more than 1 hour of mechanical ventilation during the first three days of age.

Secondary

MeasureTime frameDescription
need for intermittent mechanical ventilation (iMV)through study completion, an average of 1 yearneed for iMV at any time and its duration
second dose of surfactantthrough study completion, an average of 1 yearthe requirement of a second dose of surfactant
bradycardia episodesthrough study completion, an average of 1 yearthe number of bradycardia episodes (\<100 bpm) needing pressure inflations (PPI) during instillation
attempts to catheterizethrough study completion, an average of 1 yearthe number of attempts to catheterize the trachea was recorded
surfactant reflux casesthrough study completion, an average of 1 yearthe number of surfactant reflux cases

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026